About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company's principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory. Its HIV products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost and Vitekta. The Company's liver diseases products include Harvoni, Sovaldi, Viread and Hepsera. The Company's cardiovascular products include Letairis, Ranexa and Lexiscan/Rapiscan. Its oncology product is Zydelig. Its respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen. The Company's Nimbus Apollo program is a Phase II ready clinical program for NDI-010976 and related metabolic and liver diseases.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Exchange: NASDAQ
- Symbol: GILD
- CUSIP: 37555810
- Previous Close: $69.85
- 50 Day Moving Average: $71.76
- 200 Day Moving Average: $75.36
- 52-Week Range: $1,310,000,000.00 - $65.38
- Trailing P/E Ratio: 7.03
- Foreward P/E Ratio: 8.80
- P/E Growth: -1.69
- Market Cap: $91.50B
- Outstanding Shares: 1,310,000,000
- Beta: 1.11
- Net Margins: 44.43%
- Return on Equity: 92.36%
- Return on Assets: 29.22%
Companies Related to Gilead Sciences:
- Debt-to-Equity Ratio: 1.53%
- Current Ratio: 4.17%
- Quick Ratio: 4.00%
What is Gilead Sciences' stock symbol?
Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."
How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?
Gilead Sciences declared a quarterly dividend on Tuesday, February 7th. Shareholders of record on Thursday, March 16th will be paid a dividend of $0.52 per share on Thursday, March 30th. This represents a $2.08 annualized dividend and a yield of 2.98%. The ex-dividend date is Tuesday, March 14th. This is a boost from Gilead Sciences's previous quarterly dividend of $0.47.
Where is Gilead Sciences' stock going? Where will Gilead Sciences' stock price be in 2017?
27 brokers have issued 1 year price targets for Gilead Sciences' stock. Their forecasts range from $65.50 to $116.00. On average, they expect Gilead Sciences' stock price to reach $86.82 in the next twelve months.
When will Gilead Sciences announce their earnings?
Gilead Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, April, 26th 2017.
What are analysts saying about Gilead Sciences stock?
Here are some recent quotes from research analysts about Gilead Sciences stock:
- Jefferies Group LLC analysts commented, "Though expectations were relatively high going into the data, "sneak peek" at bic vs. dolu HTH ph.III HIV data at evening CROI press conference show GILD's integrase trending towards better efficacy vs. dolu-- explaining co's recent enthusiasm. Small study, but much needed good news for GILD and recall bictegravir will help maintain LT HIV franchise post-2025. Expect upside on increasing comfort on HIV franchise longevity given increasing dependence on HIV." (2/14/2017)
According to Zacks Investment Research, "Although Gilead’s fourth quarter results beat on both earnings and sales, the guidance for 2017 was disappointing. The HCV franchise continues to be under competitive and pricing pressure due to which the sales of Harvoni and Sovaldi have declined. Total HCV treatment starts in the U.S. were an estimated 231,000 in 2016, approximately 25,000 less than 2015. The company expects a further decline in patients starts in 2017. In addition, Gilead will lose exclusivity for Viread in 2017 in some countries outside the U.S. which should impact sales. Shares of Gilead have underperformed the biotech industry in the past one year. On a positive note, Epclusa’s uptake has been encouraging while the HIV franchise maintains momentum driven by the rapid adoption of TAF-based regimens. Strong uptake for Truvada for use in the pre-exposure prophylaxis setting should also boost sales." (2/13/2017)
- Needham & Company LLC analysts commented, "Gilead reported 4Q16 financial results yesterday. Total 4Q16 revenue of $7.32B exceeded our $6.86B and consensus $7.14B estimates, driven by strong Epclusa launch in HCV ($1.05B WW). HCV sales overall, however, continue to fall and mgmt issued 2017 sales guidance below expectations. We remain cautious given revenue trajectory and maintain HOLD." (2/8/2017)
Cowen and Company analysts commented, "Effective Jan. 1, the U.S. price of Atripla has been increased by 2.3%." (1/6/2017)
RBC Capital Markets analysts commented, "We should see BLA acceptance on CHS-1701 on or before October 9; we should see an AdComm in April 2017 and approval soon thereafter; launch timing depends on need for 180- day waiting period. While Sandoz has not disclosed the reason for its CRL, we believe the company could be set back 2-3 years." (10/3/2016)
Who owns Gilead Sciences stock?
Gilead Sciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include State Street Corp (4.59%), FMR LLC (2.97%), Franklin Resources Inc. (1.09%), Temasek Holdings Private Ltd (1.06%), Renaissance Technologies LLC (0.40%) and AQR Capital Management LLC (0.32%). Company insiders that own Gilead Sciences stock include Gayle E Wilson, Gregg H Alton, John C Martin, John F Milligan, John Francis Cogan, John W Madigan, Kevin E Lofton, Norbert W Bischofberger, Paul Rutherford Carter, Richard James Whitley and Robin L Washington.
Who sold Gilead Sciences stock? Who is selling Gilead Sciences stock?
Gilead Sciences' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Edgewood Management LLC, Levin Capital Strategies L.P., Investec Asset Management LTD, Orbimed Advisors LLC, Fred Alger Management Inc., Janus Capital Management LLC and Thornburg Investment Management Inc.. Company insiders that have sold Gilead Sciences stock in the last year include Gayle E Wilson, Gregg H Alton, John C Martin, John F Milligan, John W Madigan, Kevin E Lofton and Paul Rutherford Carter.
Who bought Gilead Sciences stock? Who is buying Gilead Sciences stock?
Gilead Sciences' stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, State Street Corp, Asset Management One Co. Ltd., FIL Ltd, Russell Investments Group Ltd., Elkfork Partners LLC, Prudential PLC and ANTIPODES PARTNERS Ltd.
How do I buy Gilead Sciences stock?
Shares of Gilead Sciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Gilead Sciences stock cost?
One share of Gilead Sciences stock can currently be purchased for approximately $69.85.